Selection of Optimal AAV Serotype for Brain-Wide Gene Delivery Following Intracerebroventricular Injection in mdx52 Mice
This study demonstrates that neonatal intracerebroventricular injection of AAVrh10 achieves superior brain-wide diffusion and neuronal transduction compared to other serotypes in mdx52 mice, offering an optimized strategy for treating central nervous system comorbidities in Duchenne muscular dystrophy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Duchenne muscular dystrophy is a severe genetic condition that causes muscles to weaken and waste away over time. It stems from a missing piece of instructions in the body's genetic code, preventing the production of a vital protein called dystrophin, which acts like a shock absorber for muscle fibers. While the physical decline of muscles is the most visible sign of the disease, many patients also face significant challenges with their thinking, behavior, and learning. This happens because the same missing protein is also needed in the brain. For years, scientists have worked on ways to deliver a working copy of the missing gene to the body using tiny, harmless viruses as delivery trucks. These trucks, known as adeno-associated viruses or AAVs, can carry genetic cargo into cells. However, getting these trucks to reach the brain is difficult because the brain is protected by a tight security barrier that keeps most things out. Furthermore, even when scientists inject the viruses directly into the fluid surrounding the brain, they often struggle to spread far enough to reach all the necessary areas.
A team of researchers at Université Paris-Saclay set out to solve this spreading problem by testing which type of viral truck works best to cover the entire brain. They focused on four different versions of the virus: two that occur naturally, one that has been chemically altered to have a special peptide tag, and one that is a hybrid created by mixing parts of different viruses. To see how well each version traveled, the scientists used a mouse model of Duchenne muscular dystrophy. They injected these viruses directly into the fluid-filled spaces inside the brain of the mice. To make the results visible, the viruses were programmed to carry a gene that makes cells glow green. The researchers then looked at the brains of the mice to see how far the green light traveled and which types of cells it turned on.
The study revealed that the timing of the injection made a massive difference. When the scientists injected the viruses into newborn mice, the green glow spread widely across the entire brain, reaching deep into the cortex and the cerebellum. In contrast, when the same injections were given to adult mice, the spread was much more limited, staying mostly close to the injection site. This suggests that the developing brain of a newborn is far more receptive to these viral deliveries than the mature brain. Among the four viral types tested, one specific version, known as AAVrh10, proved to be the most effective. Following injection into newborn mice, this virus created the broadest and brightest green glow, covering nearly the entire front part of the brain and reaching deep into the back. The other viruses, including the naturally occurring AAV9 and the hybrid AAVDJ, managed to light up only about half of the brain area or showed weaker signals. The chemically modified version, PM-AAV9, performed better than the standard AAV9 but still did not match the wide reach of AAVrh10.
Beyond just how far the virus traveled, the researchers also looked at which cells it actually entered. They found that all four versions of the virus preferred to enter nerve cells, known as neurons, rather than the support cells called astrocytes. This is a crucial detail because the missing protein in Duchenne muscular dystrophy is primarily needed in neurons to support healthy brain function. The virus AAVrh10 was not only the best at spreading but also the most efficient at turning on the green gene in the neurons it reached. In the outer layer of the brain and the hippocampus, a region critical for memory, AAVrh10 successfully entered a high percentage of the nerve cells. In the cerebellum, which controls movement, the virus found its way into the large, distinctive nerve cells known as Purkinje cells, which are essential for coordination. While the hybrid virus AAVDJ showed some ability to enter cells, it consistently performed the worst in terms of both spread and brightness.
The findings suggest that for treating the brain-related aspects of Duchenne muscular dystrophy, the choice of viral vehicle and the timing of the treatment are critical. The study indicates that AAVrh10, when delivered early in life, offers the most promising path for reaching the widespread network of neurons in the brain. This is particularly important because the specific protein missing in these patients is needed in different brain regions to prevent cognitive and behavioral issues. While the research was conducted in mice and does not yet represent a treatment for humans, it provides a clear roadmap for future therapies. It shows that by selecting the right viral truck and administering it at the right developmental stage, it is possible to overcome the brain's natural barriers and deliver genetic medicine to the cells that need it most. The work highlights that while the challenge of brain delivery is significant, the right combination of tools can make the entire brain accessible, offering hope for addressing the full spectrum of the disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.